ScienceDaily (Sep. 1, 2011) — Researchers have found that a protein variation linked by some genetic studies to Alzheimer's disease is consistently present in the brains of people with Alzheimer's. In further biochemical and cell culture investigations, they have shown that this protein, known as ubiquilin-1, performs a critical Alzheimer's-related function: it "chaperones" the formation of amyloid precursor protein, a molecule whose malformation has been directly tied to Alzheimer's pathology.
APP has been a major focus of Alzheimer's investigators for almost two decades, ever since scientists identified it as the source of so-called "protein plaques," abnormal aggregations of proteins nearly always found in the brains of Alzheimer's victims. Ubiquilin-1's significance was revealed after the UTMB researchers established ubiquilin-1's status as a chaperone protein for APP.
In the origami-like folding process by which proteins arrive at their proper shape, chaperone proteins act as, well, chaperones: they bind to their client proteins and make sure they don't misbehave.
The kind of APP misbehavior Alzheimer's researchers are most concerned about is the formation of toxic aggregations of the protein or its breakdown products, both inside and outside brain cells. Through a series of biochemical and cell-culture experiments, the UTMB team was able to show that ubiquilin-1 decreased this aggregation.
"Ubiquilin-1 prevents the APP molecule from falling into a conformation it's not supposed to be in," said UTMB associate professor Darren Boehning, co-author of the Journal of Biological Chemistry paper. "This fits with a theme we're seeing across the neurodegenerative disorders and the disorders of aging -- the idea that many of these disorders are associated with decreased quality control by chaperones."
Other authors of the Journal of Biological Chemistry paper include graduate student Emily Stieren, research scientist Amina El Ayadi, graduate student Yao Xiao, graduate student Efraín Siller, Professor Andres Oberhauser and Assistant Professor Megan Landsverk of Baylor College of Medicine. The National Institutes of Health and the Jean C. and William D. Willis Neuroscience Research Endowment supported this work.